CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
BI 1026706 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02652416
NCT02652416Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1026706 in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Trial)

Boehringer Ingelheim·interventional·Posted Jan 11, 2016·Updated Jul 11, 2019

In Brief

A Phase 1 clinical trial evaluating BI 1026706 and Placebo for Healthy. Completed, enrolled 72 participants across 1 site.

Detailed Summary

Safety and tolerability of BI 1026706 in healthy Chinese and Japanese male subjects following oral administration of single rising doses (SRD) followed by multiple rising doses (MRD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 11, 2016
Enrollment StartSep 16, 2016
Primary CompletionDec 9, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.5 years ago

Interventions

BI 1026706drug

oral administration

Placebodrug

placebo